HILDEN, Germany, and GERMANTOWN, Maryland, January 8, 2018 /PRNewswire/ --
- Goal set to exceed $140 million of NGS-related sales
in 2018, up from over $115
million in 2017
- New Enterprise Genomics Services to offer gene
panel customization capabilities to customers
- GeneReader NGS System plans include enhanced chemistry, more
powerful gene panels
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today
announced a range of product and service enhancements to its
next-generation sequencing (NGS) portfolio, which offers universal
solutions for use with any NGS sequencer as well as the GeneReader
NGS System*, the world's first complete Sample to Insight solution
based on proprietary chemistry that makes the benefits of NGS
accessible to any laboratory. QIAGEN has set a goal to exceed
$140 million in 2018 sales from this
portfolio, up from over $115 million
in 2017.
These initiatives, which include the launch of a new Enterprise
Genomics Services offering to customers for the customization of
gene panels, are designed to add momentum to QIAGEN's rapidly
growing presence in NGS, a technology that is enabling valuable
molecular insights along the continuum from basic academic research
to routine clinical healthcare.
"QIAGEN's presence in next-generation sequencing continues to
grow at a strong double-digit rate for sales, fueled by innovative
solutions for faster and better results on any NGS platform as well
as by the rapid adoption of our GeneReader NGS System," said
Peer M. Schatz, Chief Executive
Officer of QIAGEN N.V. "Our expansion plans for 2018 include the
rapid scale-up of the new Enterprise Genomics Services, which will
help customers to accelerate and de-risk the development of new
gene panels that are essential for the migration of biomedical
findings from discovery to implementation in clinical healthcare.
We also have extensive growth plans for our successful GeneReader
system with the introduction of the new, proprietary
third-generation chemistry and a series of new gene panels based on
our proprietary Digital NGS technology."
* For research use only
Click here for full press release:
https://corporate.qiagen.com/newsroom/press-releases/2017/20180108_NGS_Portfolio_Expansion?sc_lang=en
Contacts:
QIAGEN
Investor Relations
John Gilardi
+49-2103-29-11711
e-mail:ir@QIAGEN.com
Public Relations
Dr. Thomas Theuringer
+49-2103-29-11826
e-mail: pr@QIAGEN.com
SOURCE Qiagen N.V.